Law360, New York (October 29, 2007, 12:00 AM EDT) -- A judge in the multidistrict securities litigation against Forest Laboratories Inc. on Friday granted class status to a group of plaintiffs that say the drug maker provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.
Judge Richard M. Berman of the U.S. District Court for the Southern District of New York signed a certification order approving Forest Labs shareholders from Aug. 15, 2002, through July 2, 2004, as class members.
The order said that it had been filed earlier in the week...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.